Advertisement
Advertisement
REPL
Replimune Group, Inc.
23.28
USDSponsored
+1.02
+4.58%
Nov 10, 15:59 UTC -5
Closed
After-Market
23.14
-0.14
-0.60%
Replimune Group, Inc. (REPL) Earnings
REPL Earnings Reports
Positive Surprise Ratio
REPL beat 18 of 34 last estimates.
53%
Next Report
Date of Next Report
Feb 01, 2027
Estimate for Q3 27 (Revenue/ EPS)
$12.42M
/-$0.74
Implied change from Q2 27 (Revenue/ EPS)
--
/+37.04%
Implied change from Q3 26 (Revenue/ EPS)
--
/-3.90%
Replimune Group, Inc. earnings per share and revenue
On Oct 28, 2026, REPL reported earnings of -0.54 USD per share (EPS) for Q2 27, beating the estimate of -0.78 USD, resulting in a 30.99% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +23.07% price change (close before vs. close after earnings).
Looking ahead to Q3 27, -- analysts forecast an EPS of -0.74 USD, with revenue projected to reach 12.42 million USD, implying an increase of 37.04% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
Legend Biotech Corporation - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
$0.00
Actual
$0.13
Surprise
+9,900.00%
Hemab Therapeutics Holdings, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.53
Actual
-$0.57
Surprise
-8.51%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Opus Genetics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.18
Surprise
-19.68%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
MaxCyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.07
Actual
-$0.05
Surprise
+36.79%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were Replimune Group, Inc.'s earnings and revenue for the latest quarter Q2 2027?
For Q2 2027, Replimune Group, Inc. reported EPS of -$0.54, beating estimates by 30.99%, and revenue of $0.00, 0% as expectations.
How did the market react to Replimune Group, Inc.'s Q2 2027 earnings?
The stock price moved up 23.07%, changed from $13.05 before the earnings release to $16.06 the day after.
When is Replimune Group, Inc. expected to report next?
The next earning report is scheduled for Feb 01, 2027.
What are the forecasts for Replimune Group, Inc.'s next earnings report?
Based on --
analysts, Replimune Group, Inc. is expected to report EPS of -$0.74 and revenue of $12.42M for Q3 2027.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.